Meroven LLC and CURE Pharmaceutical Enter Exclusive Marketing and Distribution Agreement for Spee-D for the USA

GlobeNewswire•May 2, 2019 CHICAGO, May 02, 2019 (GLOBE NEWSWIRE) — Today, at the CPhI Conference, Meroven LLC announced a five-year agreement with CURE Pharmaceutical Corporation (CURR) to exclusively market and distribute Spee-D®, a weekly dose oral thin film Vitamin D3 in the USA. Under the terms of the agreement, Meroven LLC will be responsible for…

Cure Pharmaceutical to Present at the “Planet MicroCap Showcase 2019”

GlobeNewswire•April 30, 2019 CURE CEO to discuss expanded product pipeline and company’s continued execution into cannabinoid market. LAS VEGAS, April 30, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the Planet MicroCap Showcase at 8:30 a.m. on Wednesday, May 1, 2019…

CURE Pharmaceutical Named “Innovative Business of the Year” By Oxnard Chamber of Commerce

GlobeNewswire•April 26, 2019 OXNARD, Calif., April 26, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, has been named 2019’s Innovative Business of the Year by Oxnard Chamber of Commerce in recognition to the company’s innovative thinking for various programs, employing pioneering technology and a dedication to improving the…

Wealth Minerals Management to Host Conference Call

GlobeNewswire•April 4, 2019 Provides Update on Spin-Out of Copper Subsidiary VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN) announces a conference call with management to discuss the Company’s current operations, recently announced news on Atacama and the National Mining…

Wealth Completes US$2M Atacama Payment

Registers Ownership of the Atacama Property Wealth Minerals Ltd.April 02, 2019 10:30 ET Registers Ownership of the Atacama Property VANCOUVER, British Columbia, April 02, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), announces it has completed the US$2 million option payment for the…

CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery

GlobeNewswire•April 1, 2019 OXNARD, Calif., April 01, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has agreed to acquire Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction.…

CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction

GlobeNewswire• March 26, 2019 OXNARD, Calif., March 26, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA). The FDA provided feedback supportive of CURE’s clinical development plans for its CUREfilm…

Wealth Announces Option For 100% Of Meductic Vanadium Property

GlobeNewswire •March 13, 2019 Cancels Incentive Stock Options VANCOUVER, British Columbia, March 13, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN), announces that it has signed an option agreement giving it the right (the “Option”) to acquire a 100% interest (subject to a 2% NSR royalty)…

CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

GlobeNewswire•March 12, 2019 OXNARD, Calif., March 12, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE…